Skip to content

Study · Animal study (in vivo) · 2024

13 results

Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.

Yin Y, Li Y, Ma B, Ren C, Zhao S, Li J, Gong Y, Yang H, Li J

Advanced science (Weinheim, Baden-Wurttemberg, Germany)25 Sept 2024Cited by 15 (Europe PMC)

PMID39321430 (opens in a new tab)PMCIDPMC11578304 (opens in a new tab)DOI10.1002/advs.202405620 (opens in a new tab)PepBankPUB-39321430
Download PDFPubMedAsk about this study
Jump to 13 results

Summary

Mitochondrial-nuclear communication plays a vital role in maintaining cellular homeostasis. MOTS-c, a short peptide derived from the 12S rRNA of mitochondrial DNA, has been suggested as a retrograde mitochondrial signal. Although recent clinical studies have suggested a possible link between MOTS-c and human cancer, the role of MOTS-c in tumorigenesis has yet to be investigated. Here, MOTS-c levels are found to be reduced in both serum and tumor tissues from ovarian cancer (OC) patients, which are associated with poor patients' prognosis. Exogenous MOTS-c inhibits the proliferation, migration and invasion of OC cells, and induces cell cycle arrest and apoptosis. Mechanistically, MOTS-c interacts with LARS1 and promotes its ubiquitination and proteasomal degradation. In addition, USP7 was identified as a deubiquitinase of LARS1, and MOTS-c can attenuates USP7-mediated LARS1 deubiquitination by competing with USP7 for binding to LARS1. Besides, LARS1 was found to be increased and play an important oncogenic function in OC. More importantly, MOTS-c displays a marked anti-tumor effect on OC growth without systemic toxicity in vivo. In conclusion, this study reveals a crucial role of MOTS-c in OC and provides a possibility for MOTS-c as a therapeutic target for the treatment of this manlignacy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study13

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In vivo, MOTS‑c displayed a marked anti-tumor effect on ovarian cancer growth.

    In plain wordsIn animal tests, MOTS‑c clearly slowed ovarian cancer growth.

    Peptide
    MOTS-c
    Outcome
    DecreaseOvarian cancer growth in vivo
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    More importantly, MOTS-c displays a marked anti-tumor effect on OC growth without systemic toxicity in vivo.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In vivo, MOTS‑c showed no systemic toxicity.

    In plain wordsIn animal tests, MOTS‑c caused no toxicity across the body.

    Peptide
    MOTS-c
    Outcome
    No significant changeSystemic toxicity in vivo
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    More importantly, MOTS-c displays a marked anti-tumor effect on OC growth without systemic toxicity in vivo.
  3. 03LabIn vitro (cells)Efficacy outcome

    Exogenous MOTS‑c inhibited the proliferation of ovarian cancer cells.

    In plain wordsIn lab tests, added MOTS‑c slowed the growth of ovarian cancer cells.

    Peptide
    MOTS-c
    Outcome
    DecreaseProliferation of ovarian cancer cells
    Study

    n: not reported in source

    Ovarian cancer cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous MOTS-c inhibits the proliferation, migration and invasion of OC cells, and induces cell cycle arrest and apoptosis.
  4. 04LabIn vitro (cells)Efficacy outcome

    Exogenous MOTS‑c inhibited the migration of ovarian cancer cells.

    In plain wordsIn lab tests, added MOTS‑c reduced the movement of ovarian cancer cells.

    Peptide
    MOTS-c
    Outcome
    DecreaseMigration of ovarian cancer cells
    Study

    n: not reported in source

    Ovarian cancer cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous MOTS-c inhibits the proliferation, migration and invasion of OC cells, and induces cell cycle arrest and apoptosis.
  5. 05LabIn vitro (cells)Efficacy outcome

    Exogenous MOTS‑c inhibited the invasion of ovarian cancer cells.

    In plain wordsIn lab tests, added MOTS‑c reduced the spread of ovarian cancer cells into surrounding material.

    Peptide
    MOTS-c
    Outcome
    DecreaseInvasion of ovarian cancer cells
    Study

    n: not reported in source

    Ovarian cancer cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous MOTS-c inhibits the proliferation, migration and invasion of OC cells, and induces cell cycle arrest and apoptosis.
  6. 06LabIn vitro (cells)Efficacy outcome

    Exogenous MOTS‑c induced cell cycle arrest in ovarian cancer cells.

    In plain wordsIn lab tests, added MOTS‑c stopped ovarian cancer cells from completing their division cycle.

    Peptide
    MOTS-c
    Outcome
    IncreaseCell cycle arrest of ovarian cancer cells
    Study

    n: not reported in source

    Ovarian cancer cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous MOTS-c inhibits the proliferation, migration and invasion of OC cells, and induces cell cycle arrest and apoptosis.
  7. 07LabIn vitro (cells)Efficacy outcome

    Exogenous MOTS‑c induced apoptosis in ovarian cancer cells.

    In plain wordsIn lab tests, added MOTS‑c caused ovarian cancer cells to die.

    Peptide
    MOTS-c
    Outcome
    IncreaseApoptosis of ovarian cancer cells
    Study

    n: not reported in source

    Ovarian cancer cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous MOTS-c inhibits the proliferation, migration and invasion of OC cells, and induces cell cycle arrest and apoptosis.
  8. 08LabIn vitro (cells)Mechanism

    MOTS‑c interacted with LARS1.

    In plain wordsIn lab tests, MOTS‑c bound to the LARS1 protein.

    Peptide
    MOTS-c
    Outcome
    Not applicableInteraction of MOTS-c with LARS1
    Study

    n: not reported in source

    Ovarian cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, MOTS-c interacts with LARS1 and promotes its ubiquitination and proteasomal degradation.
  9. 09LabIn vitro (cells)Mechanism

    MOTS‑c promoted ubiquitination and proteasomal degradation of LARS1.

    In plain wordsIn lab tests, MOTS‑c increased the tagging and breakdown of the LARS1 protein.

    Peptide
    MOTS-c
    Outcome
    IncreaseLARS1 ubiquitination and proteasomal degradation
    Study

    n: not reported in source

    Ovarian cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, MOTS-c interacts with LARS1 and promotes its ubiquitination and proteasomal degradation.
  10. 10LabIn vitro (cells)Mechanism

    MOTS‑c attenuated USP7-mediated LARS1 deubiquitination by competing with USP7 for binding to LARS1.

    In plain wordsIn lab tests, MOTS‑c reduced USP7 removing the breakdown tag from LARS1.

    Peptide
    MOTS-c
    Outcome
    DecreaseUSP7-mediated LARS1 deubiquitination
    Study

    n: not reported in source

    Ovarian cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, USP7 was identified as a deubiquitinase of LARS1, and MOTS-c can attenuates USP7-mediated LARS1 deubiquitination by competing with USP7 for binding to LARS1.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 11HumanEndogenous levelObservational studyOther

    In patients with ovarian cancer, MOTS‑c levels were reduced in serum.

    In plain wordsIn patients with ovarian cancer, the body's own MOTS‑c levels in blood serum were lower.

    Peptide
    MOTS-c
    Outcome
    DecreaseMOTS-c level in serum of ovarian cancer patients
    Study

    n: not reported in source

    Outcome group
    Aging markers · Cancer

    Source sentences

    Summary
    Here, MOTS-c levels are found to be reduced in both serum and tumor tissues from ovarian cancer (OC) patients, which are associated with poor patients' prognosis.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  2. 12HumanEndogenous levelObservational studyOther

    In patients with ovarian cancer, MOTS‑c levels were reduced in tumor tissue.

    In plain wordsIn patients with ovarian cancer, the body's own MOTS‑c levels in tumor tissue were lower.

    Peptide
    MOTS-c
    Outcome
    DecreaseMOTS-c level in tumor tissue of ovarian cancer patients
    Study

    n: not reported in source

    Outcome group
    Aging markers · Cancer

    Source sentences

    Summary
    Here, MOTS-c levels are found to be reduced in both serum and tumor tissues from ovarian cancer (OC) patients, which are associated with poor patients' prognosis.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  3. 13HumanEndogenous levelObservational studyOther

    In patients with ovarian cancer, reduced MOTS‑c levels were associated with poor prognosis.

    In plain wordsIn patients with ovarian cancer, lower natural MOTS‑c levels were linked to a worse outlook.

    Peptide
    MOTS-c
    Outcome
    Not applicableAssociation of reduced MOTS-c with prognosis
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Here, MOTS-c levels are found to be reduced in both serum and tumor tissues from ovarian cancer (OC) patients, which are associated with poor patients' prognosis.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.